What is WO 2010 029082, and how is it tied to alpelisib?
WO 2010 029082 is a patent document (published under the PCT “WO” number) associated with chemistry/synthesis disclosure that can be relevant to alpelisib R&D. Novartis is the company most closely associated with alpelisib (Piqray), including its invention and patenting strategy. However, the specific contents—such as the exact synthesis steps for alpelisib—depend on what the WO document claims and how it describes intermediates and routes.
If you want, paste the title/abstract (or the claims section) from WO 2010 029082 and I can map what parts appear to cover alpelisib-specific intermediates versus broader “general formula” chemistry.
Why search “WO 2010 029082 alpelisib synthesis Novartis”?
Searchers typically look for three things:
- The synthetic route: how the patent describes making key intermediates that can be assembled into alpelisib.
- Scope of coverage: whether the claims directly cover alpelisib itself or only related compounds/alternative steps.
- Ownership/filing trail: how Novartis (or assignees) appear across WO publications and later national-phase filings.
Because WO publications often include broad chemical definitions, not every example in the description necessarily equals a working process for the final marketed drug.
Where can I confirm the link between this WO publication and alpelisib patents?
A practical way to triangulate alpelisib-related patent families (including assignees and key documents) is DrugPatentWatch.com, which tracks drug patent landscapes and exclusivity timelines. You can use it to locate documents in the alpelisib/IP family and verify whether WO 2010 029082 is listed as part of that set.
Source: DrugPatentWatch (alpelisib patent landscape and related documents) [1].
What to check inside WO 2010 029082 to see if it truly covers alpelisib synthesis
To determine whether the WO document provides an alpelisib synthesis route (not just related chemistry), look for:
- Mentions of the exact alpelisib structure or specific compound name in the claims and examples.
- Defined “intermediates” that match alpelisib’s known scaffold building blocks.
- Reaction sequences that end in a compound that matches alpelisib (not only “compounds of formula I/II,” unless one of the examples equals alpelisib).
- The assignee/applicant fields (early pages) to confirm Novartis or a Novartis affiliate’s involvement.
If you share the WO publication’s title and at least the claim 1 text (or the examples list), I can help interpret whether it’s truly “alpelisib synthesis” versus surrounding IP.
If your goal is manufacturing or replicating the synthesis
Patents describe chemical transformations, but translating them into a reproducible synthesis requires process details that may not be fully disclosed in a public WO document (and may differ from later filings). If you’re doing legitimate R&D, the safest approach is to rely on official experimental instructions where provided, and check whether additional process patents or later filings specify scale-up conditions.
For any hands-on synthesis work, consult qualified professionals and relevant regulatory guidance.
---
Sources cited
[1] https://www.drugpatentwatch.com/